Department of Internal Medicine, Division of Hematology/Oncology, Kameda Medical Center, 929 Higashi-chou, Kamogawa, Chiba 296-8602, Japan.
Department of Radiology, Kameda Medical Center, Kamogawa, Japan.
AJR Am J Roentgenol. 2019 Oct;213(4):918-924. doi: 10.2214/AJR.19.21283. Epub 2019 Jun 19.
The prognostic value of medullary abnormalities in the appendicular skeleton (AS) of patients with multiple myeloma (MM) has recently been suggested. However, functional evaluation of these abnormalities using PET/CT has not been investigated to date. This study aimed to explore the prevalence and prognostic relevance of AS medullary abnormalities depicted by PET/CT in patients with MM. This retrospective study included 228 consecutive patients with newly diagnosed, symptomatic MM who were treated with novel agents. All patients underwent pretreatment F-FDG PET/CT. There were 157 (68.9%) patients with zero AS focal lesions, 33 (14.5%) with one to three AS focal lesions, and 38 (16.7%) with more than three AS focal lesions on pre-treatment PET/CT. Patients with more than three AS focal lesions showed significantly shorter progression-free survival (PFS) and overall survival (OS) than did those with fewer lesions (both, < 0.001). In multivariate analysis, the presence of more than three AS focal lesions remained prognostic for both PFS and OS (both, < 0.001). Furthermore, the presence of more than three AS focal lesions discriminated patients with both significantly shorter PFS and significantly shorter OS even among patients with established high-risk parameters, including high-risk cytogenetic abnormalities, advanced disease stage, and established high-risk PET/CT findings. The presence of more than three focal lesions in the AS on pretreatment PET/CT was an independent predictor of poor survival in patients with newly diagnosed MM. Remarkably, this finding discriminated patients with shorter survival from among those with established high-risk factors. Evaluation of findings in the AS may complement and improve the prognostic performance of known stratification systems as well as PET/CT.
髓性异常在多发性骨髓瘤(MM)患者四肢骨骼(AS)中的预后价值最近已被提出。然而,迄今为止尚未使用 PET/CT 对这些异常进行功能评估。本研究旨在探讨 MM 患者 AS 髓性异常在 PET/CT 上的发生率及其与预后的相关性。
这项回顾性研究纳入了 228 例新诊断、有症状的 MM 患者,这些患者接受了新型药物治疗。所有患者均接受了预处理 F-FDG PET/CT 检查。157 例(68.9%)患者在预处理 PET/CT 上无 AS 局灶性病变,33 例(14.5%)患者有 1-3 个 AS 局灶性病变,38 例(16.7%)患者有 3 个以上 AS 局灶性病变。与病变较少的患者相比,有 3 个以上 AS 局灶性病变的患者无进展生存期(PFS)和总生存期(OS)显著缩短(均,<0.001)。多变量分析显示,存在 3 个以上 AS 局灶性病变与 PFS 和 OS 均相关(均,<0.001)。此外,即使在具有既定高危参数的患者中,包括高危细胞遗传学异常、晚期疾病分期和既定高危 PET/CT 发现,存在 3 个以上 AS 局灶性病变仍然可以预测 PFS 和 OS 更短。
预处理 PET/CT 上 AS 中存在 3 个以上局灶性病变是新诊断 MM 患者生存不良的独立预测因素。值得注意的是,这一发现可以区分生存时间较短的患者和具有既定高危因素的患者。AS 病变的评估可以补充并提高已知分层系统以及 PET/CT 的预后性能。